Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
Please log in
You must be logged in to send the contact request.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
03.02.04 Other equipment for immunochemistry and immunology
Other equipment for immunochemistry and immunology
03 Diagnostic tests
03.07 Other diagnostics
Product category: Immuno assay testing
Serological COVID-19 ELISA kit
Icosagen Covid-19 ELISA kit provides a rapid and easy method for semiquantitative determination of both IgG and IgM antibodies against SARS-CoV-2 (2019-nCoV) Spike and Nucleocapsid proteins in human sera and plasma.
APPLICATION The kit includes reagents necessary to analyze SARS-CoV-2 specific antibodies in up to 46 samples using one kit. ELISA titers can be determined in 23 serum or plasma samples.
Kit description: High sensitivity: Limit of detection 1-8 pg/mL Can be used to detect small quantities of CDNF starting from 15 pg/mL Assay range 15 pg/mL to 960 pg/mL High affinity of the CDNF antibodies (antibodies raised against full length recombinant CDNF) The entire test procedure can be performed at room temperature Short testing time (2 hours)
The kit has been developed based on Icosagens unique CDNF antibodies, which are raised against full-length recombinant protein expressed in mammalian cell culture. As is the case with many of the other antibodies in Icosagen's portfolio, they have high affinity and high specificity (no cross reactivity to other nerve growth factors).
Monoclonal antibodies against SARS-CoV-2 Nucleocapsid protein
Icosagen has developed an antibody pair against SARS-CoV-2 Nucleocapsid protein with subpicomolar affinities. As nucleocapsid protein is the most abundant, it is a preferred diagnostic target when developing an antigen assay. We already see that this pair can detect the nucleocapsid protein even as low concentration as 6 pg/ml. Further studies with clinical samples from COVID-19 patients will start soon to detect the virus infection.
You can find more information from the attached PDF file.
Icosagen discovers premium antibodies with great diversity, affinity, and developability, as well as producing high-quality recombinant proteins/antibodies for its partner companies. Success of our scientific team stems from the unique combination of proprietary technologies, and the companys extensive competence related to the protein biochemistry, molecular cloning and cell line engineering. Icosagen is putting 20 years of experience in pharma field into developing relevant diagnostics catalogue.